NO975729L - Forbindelser og peptider som binder til etytropoietinreseptoren - Google Patents

Forbindelser og peptider som binder til etytropoietinreseptoren

Info

Publication number
NO975729L
NO975729L NO975729A NO975729A NO975729L NO 975729 L NO975729 L NO 975729L NO 975729 A NO975729 A NO 975729A NO 975729 A NO975729 A NO 975729A NO 975729 L NO975729 L NO 975729L
Authority
NO
Norway
Prior art keywords
hoc
amino
receptor
ethytropoietin
compounds
Prior art date
Application number
NO975729A
Other languages
English (en)
Other versions
NO975729D0 (no
NO318783B1 (no
Inventor
Nicholas C Wrighton
William J Dower
Ray S Chang
Arun K Kashyap
Linda K Jolliffe
Dana Johnson
Original Assignee
Ortho Pharma Corp
Affymax Yechnologies Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,631 external-priority patent/US5830851A/en
Priority claimed from US08/484,635 external-priority patent/US5773569A/en
Application filed by Ortho Pharma Corp, Affymax Yechnologies Nv filed Critical Ortho Pharma Corp
Publication of NO975729D0 publication Critical patent/NO975729D0/no
Publication of NO975729L publication Critical patent/NO975729L/no
Publication of NO318783B1 publication Critical patent/NO318783B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19975729A 1995-06-07 1997-12-05 Peptid som binder til erytropoietinreseptoren og anvendelse derav, samt farmasoytiske blandinger som inneholder peptidet. NO318783B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/484,631 US5830851A (en) 1993-11-19 1995-06-07 Methods of administering peptides that bind to the erythropoietin receptor
US08/484,635 US5773569A (en) 1993-11-19 1995-06-07 Compounds and peptides that bind to the erythropoietin receptor
PCT/US1996/009810 WO1996040749A1 (en) 1995-06-07 1996-06-07 Compounds and peptides that bind to the erythropoietin receptor

Publications (3)

Publication Number Publication Date
NO975729D0 NO975729D0 (no) 1997-12-05
NO975729L true NO975729L (no) 1998-02-05
NO318783B1 NO318783B1 (no) 2005-05-09

Family

ID=27048076

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975729A NO318783B1 (no) 1995-06-07 1997-12-05 Peptid som binder til erytropoietinreseptoren og anvendelse derav, samt farmasoytiske blandinger som inneholder peptidet.

Country Status (18)

Country Link
EP (2) EP0886648B8 (no)
JP (3) JP4050314B2 (no)
KR (1) KR100459984B1 (no)
CN (1) CN1192748A (no)
AT (1) ATE254138T1 (no)
AU (1) AU712713B2 (no)
BR (1) BR9609006A (no)
CA (1) CA2223833C (no)
CZ (1) CZ391097A3 (no)
DE (1) DE69630708T2 (no)
ES (1) ES2210374T3 (no)
HU (1) HUP9901069A2 (no)
IL (1) IL122417A0 (no)
NO (1) NO318783B1 (no)
NZ (1) NZ310804A (no)
PL (1) PL185040B1 (no)
TR (1) TR199701557T2 (no)
WO (1) WO1996040749A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE19904406A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
DE19904396A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP4975966B2 (ja) 2002-12-31 2012-07-11 ネクター セラピューティクス ケトンまたは関連する官能基を含むポリマー試薬
EP1628686A2 (en) 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
KR20060028675A (ko) 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
NZ543935A (en) 2003-05-12 2008-06-30 Affymax Inc Peptides that bind to the erythropoietin receptor
OA13164A (en) 2003-05-12 2006-12-13 Affymax Inc Novel peptides that bind to the erythropoietin receptor.
WO2005000360A2 (en) 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage
PL1675622T3 (pl) 2003-09-17 2017-11-30 Nektar Therapeutics Proleki na bazie wieloramiennego polimeru
CA2758460C (en) 2003-12-16 2014-09-23 Nektar Therapeutics Methods of preparing monodisperse oligo (ethylene glycol) reagent compositions
JP2007529475A (ja) * 2004-03-17 2007-10-25 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 等比体積の形態変換
WO2005107815A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
JP2008519589A (ja) * 2004-11-10 2008-06-12 アプラゲン ゲーエムベーハー 造血を促進する分子
KR20070108140A (ko) * 2004-11-11 2007-11-08 아피맥스, 인크. 에리트로포이에틴 수용체에 결합하는 신규한 펩타이드
JPWO2006115274A1 (ja) * 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20100145006A1 (en) * 2005-06-23 2010-06-10 Hans-Georg Frank Supravalent compounds
EA015672B1 (ru) * 2005-08-05 2011-10-31 Араим Фармасьютикалз, Инк. Тканезащитные пептиды и их применения
MX2008011389A (es) * 2006-03-09 2009-01-26 Aplagen Gmbh Moleculas modificadas las cuales promueven hematopoyesis.
CN101528263B (zh) 2006-06-30 2013-01-23 Sku资产管理有限公司 用于癌症的先天性免疫方法的缀合物
JP2010520855A (ja) 2007-01-31 2010-06-17 アフィーマックス・インコーポレイテッド 修飾基をポリペプチドおよびその他の高分子に結合するための窒素ベースのリンカー
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
CA2719940A1 (en) * 2008-03-26 2009-11-26 Orthologic Corp. Methods for treating acute myocardial infarction
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
JP5766118B2 (ja) 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP5694171B2 (ja) * 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
US20120190574A1 (en) * 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
DK2590666T3 (en) 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
WO2013171810A1 (ja) 2012-05-14 2013-11-21 パナソニック株式会社 耐熱性抗体提示ファージを得る方法
CN103450348B (zh) * 2012-05-29 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 一种促红细胞生成素模拟肽、其制备方法和用途
CN106608906A (zh) * 2015-10-22 2017-05-03 天津药物研究院有限公司 一种具有刺激红细胞生成功能的环形多肽的制备及其应用
CN106928338A (zh) * 2015-12-31 2017-07-07 杭州阿德莱诺泰制药技术有限公司 促红细胞生成素肽及衍生物和聚合物、制备方法和应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
CN113166203A (zh) * 2018-09-14 2021-07-23 Epo医药株式会社 抗促红细胞生成素受体肽
CA3142758A1 (en) 2019-06-10 2020-12-17 Respira Therapeutics,Inc. Carrier-based formulations and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers

Also Published As

Publication number Publication date
EP1510524A2 (en) 2005-03-02
PL185040B1 (pl) 2003-02-28
AU712713B2 (en) 1999-11-11
JP2007277264A (ja) 2007-10-25
JP2009280616A (ja) 2009-12-03
CA2223833A1 (en) 1996-12-19
KR100459984B1 (ko) 2005-06-20
DE69630708T2 (de) 2004-08-05
ATE254138T1 (de) 2003-11-15
EP0886648B1 (en) 2003-11-12
JPH11507367A (ja) 1999-06-29
NO975729D0 (no) 1997-12-05
EP0886648A4 (en) 2000-01-12
WO1996040749A1 (en) 1996-12-19
NO318783B1 (no) 2005-05-09
BR9609006A (pt) 1999-12-14
CN1192748A (zh) 1998-09-09
NZ310804A (en) 1998-10-28
AU6166796A (en) 1996-12-30
IL122417A0 (en) 1998-06-15
JP4050314B2 (ja) 2008-02-20
HUP9901069A2 (hu) 1999-07-28
ES2210374T3 (es) 2004-07-01
KR19990022656A (ko) 1999-03-25
PL323858A1 (en) 1998-04-27
EP0886648A1 (en) 1998-12-30
CZ391097A3 (cs) 1998-07-15
EP0886648B8 (en) 2004-03-03
CA2223833C (en) 2010-12-21
EP1510524A3 (en) 2006-06-07
TR199701557T2 (xx) 2002-06-21
DE69630708D1 (de) 2003-12-18

Similar Documents

Publication Publication Date Title
NO975729L (no) Forbindelser og peptider som binder til etytropoietinreseptoren
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
DK0765394T3 (da) Oprensede Myceliopthora-laccaser og nukleinsyrer der koder for disse
FI954805A0 (fi) Menetelmiä insuliininkaltaisen kasvutekijän sitojaproteiinien käyttämiseksi
DE59409672D1 (de) Festphasensynthese von Oligoribonucleotiden
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
NO950477D0 (no) Aminosyrederivater
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
SE9602822D0 (sv) New receptor
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
DK0923644T3 (da) G-koblet receptor, der udviser selektiv selektivitet for ATP
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof
DE69315730T2 (de) Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
NO974713L (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
CA2199843A1 (en) Novel PKA-Binding Proteins and Uses Thereof
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
FR2710241B3 (fr) Composition énergétique à base d'acides aminés glycogéniques.
EP0716146A3 (en) A novel stem cell marker protein, antibodies thereto, compositions thereof and nucleotide sequences encoding said protein

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees